2024 US study links Ozempic and Wegovy, containing semaglutide, to a 30% higher risk of stomach paralysis (gastroparesis) in users.
A recent US study has found that popular diabetes and weight loss medications, such as Ozempic and Wegovy, have been linked with an increased risk of developing stomach paralysis (gastroparesis), a condition that weakens stomach muscles and delays digestion. Both medications contain the protein semaglutide, similar to the hormone glucagon-like peptide-1 (GLP-1). The study, presented at the Digestive Disease Week 2024 conference, suggests that users of these drugs have a 30% higher risk of developing gastroparesis compared to non-users.
May 26, 2024
4 Articles